Giovine Capital Group’s Impax Laboratories, Inc. IPXL Stock Holding History

Giovine Capital Group’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-59,805	Closed	-$2.56M	–	40
2015 Q4	$2.56M	Sell	59,805 -63,048	-51%	-$2.52M	3.72%	6
2015 Q3	$4.33M	Sell	122,853 -3,840	-3%	-$173K	3.32%	10
2015 Q2	$5.82M	Buy	+126,693	New	+$6.01M	4.12%	3

Other funds holding IPXL

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Hound Partners New York $863M AUM 11.22% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PCM

Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Giovine Capital Group's IPXL Position: Q1 2016 in Review

Giovine Capital Group sold out of Impax Laboratories, Inc. (IPXL) in Q1 2016, closing a stake of 59,805 shares — an estimated $2.56M sold.

Giovine Capital Group first reported a position in IPXL in Q2 2015 and held it in 3 quarters. The position peaked at $5.82M in Q2 2015. 195 funds tracked by Wall St. Rank hold IPXL as of Q1 2016.

Giovine Capital Group reported no remaining Impax Laboratories, Inc. position as of Q1 2016 after selling out during the quarter.
Giovine Capital Group sold 59,805 Impax Laboratories, Inc. shares in Q1 2016, an estimated $2.56M.
Giovine Capital Group first reported a position in Impax Laboratories, Inc. in Q2 2015 and held it in 3 quarters.
Giovine Capital Group's Impax Laboratories, Inc. position peaked at $5.82M in Q2 2015.
195 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2016.

Based on Giovine Capital Group's 13F filing for Q1 2016.